Search Results

Bionomics Limited announced it has entered into a securities purchase agreement with an institutional accredited investor to purchase American Depository Shares and accompanying warrants in a three-tranche private placement.

Bionomics Limited announced that Spyridon “Spyros” Papapetropoulos, M.D., PhD, President and Chief Executive Officer of Bionomics will be giving an oral presentation and presenting two posters about BNC210 as a potential treatment for social anxiety disorder and post-traumatic stress disorder at the 2024 American Society of Clinical Psychopharmacology Annual Meeting taking place May 28 – 31 in Miami Beach, Florida.

Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company) today announced that it will be presenting at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 in New York, NY.

Bionomics Limited, a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system disorders with high unmet medical need, provided a 2023 review and its outlook for 2024.

Bionomics Limited announced the release of the full dataset analysis from its Phase 2b ATTUNE trial in patients with post-traumatic stress disorder.

Bionomics Limited announced that it will be presenting at the Biotech Showcase™ 2024 taking place January 8-10 in San Francisco, California.